Retrophin takes on Questcor with ACTH analog, files for IPO
This article was originally published in Scrip
Executive Summary
Retrophin shares are trading for about twice as much as they did at the beginning of 2013 in the Over the Counter market, so it makes sense for the company focused on therapies for rare and serious diseases to pursue an initial public offering that will move its stock to the Nasdaq index and raise $40m to fund assets recently added to Retrophin's development pipeline.
You may also be interested in...
Mallinckrodt's FTC Settlement Seems A Blip For Acthar Blockbuster
Company anticipates steady sales of its blockbuster treatment for infantile spasms and other severe conditions for many years, despite agreement to out-license a potential competitor as part of settlement with US trade commission. Settlement resolving investigation into earlier Questcor acquisition also includes $100m fine.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.